ARS Pharmaceuticals (SPRY) Net Margin (2022 - 2025)
Historic Net Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 163.66%.
- ARS Pharmaceuticals' Net Margin rose 8879800.0% to 163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.59%, marking a year-over-year increase of 22925600.0%. This contributed to the annual value of 8.97% for FY2024, which is 1812256400.0% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Net Margin stood at 163.66% for Q3 2025, which was up 8879800.0% from 302.95% recorded in Q2 2025.
- ARS Pharmaceuticals' Net Margin's 5-year high stood at 54.51% during Q4 2024, with a 5-year trough of 206030.0% in Q2 2023.
- For the 4-year period, ARS Pharmaceuticals' Net Margin averaged around 28230.81%, with its median value being 1070.74% (2022).
- As far as peak fluctuations go, ARS Pharmaceuticals' Net Margin plummeted by 2000000000bps in 2023, and later soared by 2000000000bps in 2024.
- ARS Pharmaceuticals' Net Margin (Quarter) stood at 3507.94% in 2022, then crashed by -5773bps to 206030.0% in 2023, then soared by 100bps to 54.51% in 2024, then plummeted by -400bps to 163.66% in 2025.
- Its Net Margin stands at 163.66% for Q3 2025, versus 302.95% for Q2 2025 and 466.29% for Q1 2025.